ED50 and ED95 of Remifentanil for Intubation Without NOL Variation
Status:
Completed
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
Our aim, in this study, is to elucidate the optimal dosing range (ED50 and ED95) of bolus
remifentanil in order to counter the painful stimuli resulting from direct laryngoscopy and
tracheal intubation by using the NOL index. In order to maximize the clinical relevance of
our findings, induction of general anesthesia will be done with standard medications and
doses and laryngoscopy will be done with the Macintosh laryngoscope, the most common tool
used for intubation in the operating room